Pharsight

1. Drug name - DIFFERIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7834060	GALDERMA LABS LP	Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders	Mar, 2023 (5 months from now)
US7868044	GALDERMA LABS LP	Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid	Mar, 2023 (5 months from now)
US8703820	GALDERMA LABS LP	Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders	Mar, 2023 (5 months from now)
US7838558	GALDERMA LABS LP	Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders	Mar, 2023 (5 months from now)
US7737181	GALDERMA LABS LP	Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders	Aug, 2024 (1 year, 10 months from now)
US7579377	GALDERMA LABS LP	Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders	Feb, 2025 (2 years from now)
US8709392	GALDERMA LABS LP	Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers	Sep, 2026 (3 years from now)
US8435502	GALDERMA LABS LP	Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers	Sep, 2026 (3 years from now)
US7998467	GALDERMA LABS LP	Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers	May, 2028 (5 years from now)

Treatment: Treatment of acne; Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.3%	GEL;TOPICAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.